Franklin Genomic Advancements ETF (HELX)

BATS: HELX · IEX Real-Time Price · USD
+0.23 (0.71%)
Jul 22, 2024, 12:10 PM EDT - Market open
Assets $9.74M
Expense Ratio 0.50%
PE Ratio 21.08
Shares Out 300,000
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return +3.89%
Volume 25,010
Open 32.58
Previous Close 32.29
Day's Range 32.40 - 32.61
52-Week Low 25.26
52-Week High 33.98
Beta 1.01
Holdings 62
Inception Date Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

Asset Class Equity
Category Health
Region Global
Stock Exchange BATS
Ticker Symbol HELX
ETF Provider Franklin Templeton

Top 10 Holdings

45.48% of assets
Name Symbol Weight
Medpace Holdings, Inc. MEDP 7.24%
Vertex Pharmaceuticals Incorporated VRTX 5.62%
Regeneron Pharmaceuticals, Inc. REGN 5.30%
Krystal Biotech, Inc. KRYS 4.78%
Danaher Corporation DHR 4.70%
Eli Lilly and Company LLY 4.56%
Thermo Fisher Scientific Inc. TMO 4.43%
Natera, Inc. NTRA 3.11%
Samsung BioLogics Co Ltd 207940.KS 3.09%
AstraZeneca PLC AZN 2.66%
View More Holdings


There is no news available yet.